Table 7.

β-Galactosidase activity conferred byARE1-lacZ and ARE2-lacZ fusions during changes in heme or due to mutations in transcription factors HAP1and ROX1

Strain (condition or genotype)β-Galactosidase activity (fold change relative to wild type)c
ARE1-lacZARE2-lacZ
TKY22 (50 μg of δ-ALA/ml)1.8 ± 0.1 (1.0)85 ± 17 (1.0)
TKY22 (0.5 μg of δ-ALA/ml)9.3 ± 0.2 (5.2)9.0 ± 1.5 (0.11)
BWG 1-7aa1.9 ± 0.2 (1.0)155 ± 19 (1.0)
LPY22 (hap1)1.7 ± 0.3 (0.9)25 ± 5.0 (0.16)
RZ53-6b0.91 ± 0.17 (1.0)43 ± 4.7 (1.0)
RZ53-6/rox14.6 ± 0.87 (5.1)130 ± 20 (3.0)
  • a The hap1 mutant was created in the BWG 1-7a background.

  • b RZ53-6 is the wild-type strain isogenic to the rox1 mutant.

  • c β-Galactosidase activity is reported as nanomoles ofo-nitrophenyl-β-d-galatopyranoside hydrolyzed per minute per milligram of protein and is the average of two independent transformants assayed in duplicate over 3 days.